Balanoposthitis

1. SGLT2 inhibitors raise the risk of balanoposthitis in humans (OR 3.44, CI: 1.73-6.86, p = 0.001).

   “balanoposthitis (10 vs. 42 cases; OR 3.44, CI: 1.73-6.86, p = 0.001) were also significantly increased.”

   Humansheart failure without diabetes, advanced kidney/liver disease, cancer, or immunodeficiency5-year follow-up

   Increasing Risk of Fournier’s Gangrene and Other Rare Genital Infections in Heart Failure Patients with and without Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): A Multicenter Cohort Study

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on SGLT2 inhibitors